If I made (a poor technical) reference to biphenotypic acute leukaemia t-cell with no inversions or over-expressions I suspect you are one of but a few who would understand my interest in CYP amongst one or two other bio-tech companies.
Ann: Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX, page-38
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.005(1.96%) |
Mkt cap ! $46.70M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.0¢ | 25.5¢ | $2.003K | 7.837K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 62856 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.28pm 18/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |